Iqbal S, Rankin C, Lenz HJ, et al. (2011) A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol
Introduction
An estimated 9,760 new cases of gallbladder and other biliary cancers are diagnosed each year in the United States [1]. The highest prevalence of gallbladder tumors and cholangiocarcinomas in the United States is in Native Americans, for reasons that are unclear. Other countries with high rates of gallbladder cancer are Chile, Bolivia, and Mexico [2]
Median survival for those presenting with locally advanced or metastatic gallbladder or cholangiocarcinoma is approximately 3–6 months, and overall 5-year survival for those with biliary tumors is less than 5% [1]. Additionally, there have been several phase II studies that have reported single-agent activity for the nucleoside analog gemcitabine [8–10].
Eckel and colleagues reported a pooled analysis and review of all chemotherapy trials that had been done in biliary tract cancers. They found that the highest response rate combinations were gemcitabine with fluoropyrimidines and/or platinum [12]
Patients and methods
Treatment Assessments: Baseline assessments included medical history and physical examination, performance status, CBC with differential and platelet count, bilirubin, SGOT and SGPT, creatinine clearance, and diagnostic tumor imaging.
Introduction
An estimated 9,760 new cases of gallbladder and other biliary cancers are diagnosed each year in the United States [1]. The highest prevalence of gallbladder tumors and cholangiocarcinomas in the United States is in Native Americans, for reasons that are unclear. Other countries with high rates of gallbladder cancer are Chile, Bolivia, and Mexico [2]
Median survival for those presenting with locally advanced or metastatic gallbladder or cholangiocarcinoma is approximately 3–6 months, and overall 5-year survival for those with biliary tumors is less than 5% [1]. Additionally, there have been several phase II studies that have reported single-agent activity for the nucleoside analog gemcitabine [8–10].
Eckel and colleagues reported a pooled analysis and review of all chemotherapy trials that had been done in biliary tract cancers. They found that the highest response rate combinations were gemcitabine with fluoropyrimidines and/or platinum [12]
Patients and methods
Treatment Assessments: Baseline assessments included medical history and physical examination, performance status, CBC with differential and platelet count, bilirubin, SGOT and SGPT, creatinine clearance, and diagnostic tumor imaging.
No comments:
Post a Comment